HealthDay | September 15, 2021
Older children, Black and Hispanic children, and children from families with lower income who attended school remotely during the pandemic in 2020 experienced disproportionate mental health difficulties, according to a study published online in JAMA Network Open by Matthew Hawrilenko, PhD, and colleagues.
MyNorthwest | September 14, 2021
Nathan Sackett, MD, MS, says the main goal surrounding decriminalization of psychedelic substances is to make it so that they can be used in controlled, medical settings, rather than recreationally.
The Washington Post | September 13, 2021
The isolation and inactivity of the pandemic took a mental toll, but experts such as Soo Borson, PhD, say there are ways to improve your memory and thinking.
The Washington Post | September 13, 2021
Scientists speculate that the pandemic’s toll on daily life and mental health may a driving force behind young adults’ increased consumption of marijuana and psychedelic drugs. Using substances to reduce anxiety can increase the risk of development of substance use disorders or dependence, says Susan Stoner, PhD.
Newsmax | September 11, 2021
Experts say we may experience an "anniversary reaction" to 9/11 and warn that the same mental challenges that we faced 20 years ago are being repeated during COVID-19. Jennifer Erickson, DO, is quoted.
UW Magazine | September 11, 2021
Did you forget a name? Lose track of your keys? Or draw a blank on why you walked into the dining room? Pamela Dean, PhD, says it may be due to an attention lapse.
Kiro 7 | September 8, 2021
Nathan Sackett, MD, MS, says studies are showing that compounds like psilocybin and other psychedelics can have a major impact on treating mental disorders, including post-traumatic stress disorder, depression and anxiety and addiction.
Vice | September 8, 2021
Resilience isn’t a trait you have; it’s something you do. Michele Bedard-Gilligan, PhD, talks about what being resilient means and the many forms it can take.
Drug Discovery & Development | September 7, 2021
The University of Minnesota Medical School has developed a therapeutic vaccine for opioid use disorder that is the subject of a new Phase 1 randomized placebo-controlled clinical trial. Marco Pravetoni, PhD, is leading the drug discovery research and will join the UW Medicine Garvey Institute for Brain Health Solutions in 2022.
The New York Times | September 7, 2021
Caffeine has a well-justified reputation for being an energy booster, but its cumulative effect can have the opposite effect, says Mark Stein, PhD
